Temperature as a determining factor in the occurrence of Legionella sp. bacteria in hot water systems in hospitals and social welfare homes.

Introduction And Objective: Water in installations in hospitals and social welfare homes (SWHs) should meet the requirements of the Directive of the European Parliament and of the Council on the quality of water intended for human consumption and national regulations issued on its basis. At present, 60 species of bacteria of the genus Legionella sp. are known (of which 30 are considered as pathogenic for humans), and more than 80 serologic groups.

Strategies for coping with stress, emotional control and occupational burnout among surgical nurses.

Introduction And Objective: Nursing staff constitute 59% of the total number of health care workers worldwide - a total of 27.9 million people. The aim of the study is assessment of the prevalence of stress, including strategies for coping with stress, emotional control, and occupational burnout syndrome, as well as the effect of chronic stress on occupational burnout among surgical nurses.

Thermal radiation transferred to the guided modes of optical interference coatings.

An electromagnetic model is developed to predict the thermal radiation which is trapped in a multilayer structure and transferred to its guided modes. The theory is based on the electromagnetic power supplied by the thermal currents given by the fluctuation-dissipation theorem. The source of the radiation is the ambient temperature or that caused by the optical absorption of the component subjected to spatio-temporal illumination.

Development of Cilofexor, an intestinally-biased Farnesoid X Receptor agonist, for the treatment of fatty liver disease.

The farnesoid X receptor (FXR) is a nuclear receptor that controls bile acid, lipid, and cholesterol metabolism. FXR-targeted drugs have shown promise in late-stage clinical trials for non-alcoholic steatohepatitis. Herein, we used clinical results from our first non-steroidal FXR agonist, Px-102 (4-[2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methoxy]phenyl]cyclopropyl] benzoic acid), to develop cilofexor, a potent, non-steroidal FXR agonist with a more manageable safety profile.